XERS vs. TSVT, FHTX, TELO, PBYI, NBTX, AEON, ACIU, HOWL, PRLD, and VNDA
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include 2seventy bio (TSVT), Foghorn Therapeutics (FHTX), Telomir Pharmaceuticals (TELO), Puma Biotechnology (PBYI), Nanobiotix (NBTX), AEON Biopharma (AEON), AC Immune (ACIU), Werewolf Therapeutics (HOWL), Prelude Therapeutics (PRLD), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.
Xeris Biopharma received 116 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 69.50% of users gave Xeris Biopharma an outperform vote while only 58.97% of users gave 2seventy bio an outperform vote.
Xeris Biopharma has higher revenue and earnings than 2seventy bio. Xeris Biopharma is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
Xeris Biopharma presently has a consensus target price of $4.88, indicating a potential upside of 176.99%. 2seventy bio has a consensus target price of $13.17, indicating a potential upside of 183.76%. Given 2seventy bio's higher possible upside, analysts plainly believe 2seventy bio is more favorable than Xeris Biopharma.
Xeris Biopharma has a net margin of -37.98% compared to 2seventy bio's net margin of -216.73%. 2seventy bio's return on equity of -59.19% beat Xeris Biopharma's return on equity.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 2.6% of 2seventy bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, 2seventy bio had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 4 mentions for 2seventy bio and 0 mentions for Xeris Biopharma. 2seventy bio's average media sentiment score of 0.89 beat Xeris Biopharma's score of 0.00 indicating that 2seventy bio is being referred to more favorably in the news media.
Summary
Xeris Biopharma beats 2seventy bio on 11 of the 18 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
